Israel’s aMoon Joins $110 Million Investment In SOPHIA GENETICS

Money

We’ve come a long way in Israel since the days when the country depended on every dime from tourism and the export of oranges.

Sophia Genetics, a Swiss Medtech company, raised $110 Million in a series F financing round which was led by an Israeli venture capital firm aMoon, an Israel based life sciences venture capital firm. So Startup Nation even invests its money in Europe.

We’ve come a long way in Israel since the days when the country depended on every dime from tourism and the export of oranges.

Japan’s Hitachi Group co-led the round, which was also participated by Credit Suisse, Swisscom Ventures, Endeavour Vision, Generation Investment Management, and the Pictet group.

SOPHIA GENETICS combines expertise in life sciences and medical disciplines with mathematical capabilities in data computing. Its stated mission is to bring data analytics solutions to market, to support healthcare professionals by maximizing the power of Data-Driven Medicine.

Yair Schindel, MD, Co-Founder & Managing Partner of the aMoon Fund, wrote on LinkedIn “SOPHiA GENETICS – incredible company, exceptional leadership! Jurgi Camblong & Troy Cox – On behalf of myself, Tomer Berkovitz and the entire aMoon Fund team, we’re honored to partner with you to help accelerate genomics globally for the benefit of patients and their families.”
“The overall demand for data-driven medicine is rapidly growing, and the next step is to successfully combine multiple sources of data to better address clinicians’ needs,” Dr. Tomer Berkovitz, Partner & CFO of aMoon said. “With this shift, more complex data will be generated, and we believe that SOPHIA’s decentralized model will play a pivotal role in empowering health organizations to offer better patient care.”

Share and Enjoy !


Read more about: ,

Leave a Reply

Your email address will not be published. Required fields are marked *